The content on this site is intended for healthcare professionals only
Dr Ibrahim Aldoss speaks to ecancer about his talk at the ALL Assembly 2021. He discusses the optimal use of asparaginase for ALL and initially gives a brief history of the drug and its role in cancer treatment.
He then discusses the use of aspariginase for ALL treatment. Dr Aldoss talks about the toxicity profile and the age limit for asparignase use in treating ALL. He also mentions the optimal doses of this drug for children and adults.
Dr Aldoss lists some toxicity related complications for asparaginase such as pancreatitis, thrombosis and hypersensitivity to this drug. He concludes by discussing when to switch drugs for treating ALL.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Encouraging results using mismatched unrelated donors in stem cell transplantation
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
Choosing wisely in multiple myeloma
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL
